Analyst Price Target is $8.50
▲ +152.98% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for NGM Biopharmaceuticals in the last 3 months. The average price target is $8.50, with a high forecast of $25.00 and a low forecast of $4.00. The average price target represents a 152.98% upside from the last price of $3.36.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in NGM Biopharmaceuticals. This Buy consensus rating has held steady for over two years.
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.